Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effectiveness of Butylphthalide on Dynamic Cerebral Autoregulation in Patients With Acute Ischemic Stroke. (EBCAS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03413202
Recruitment Status : Recruiting
First Posted : January 29, 2018
Last Update Posted : July 28, 2020
Sponsor:
Information provided by (Responsible Party):
Yi Yang, The First Hospital of Jilin University

Brief Summary:
This is a randomized, triple-blind, placebo-controlled, multicenter clinical trial. investigators plan to enroll 774 eligible patients, which will be randomized into either the butylphthalide (NBP) or placebo group in a 2:1 ratio.The main purpose of this study is to determine whether butylphthalide can improve dynamic Cerebral Autoregulation (dCA) in large-artery atherosclerosis acute ischemic stroke.

Condition or disease Intervention/treatment Phase
Acute Ischemic Stroke Drug: butylphthalide(NBP) Drug: placebo Phase 4

Detailed Description:

Cerebral stroke, the first cause of death in China, seriously affects the health and living of people.Its high incidence, disability, mortality and recurrence rate give a heavy burden on the family, society and country. According to TOAST classification, large-artery atherosclerosis ischemic stroke is one of the most common subtypes, and majority experts demonstrate its dynamic Cerebral Autoregulation (dCA) is impaired in affected hemisphere.

Thrombolytic therapy with intravenous tissue plasminogen activator (tPA), which remains the only therapeutic drug for acute ischemic stroke approved by the US Food and Drug Administration, is limited by the narrow time window of thrombolysis, bleeding complications, or high costs. Other treatment strategies mainly utilize therapeutic agents to prevent or reduce cell damage from ischemia. Butylphthalide (NBP) is a multiple target drug for the treatment of acute mild to moderate ischemic cerebral stroke.

Cerebral autoregulation (CA) is the main mechanism that maintains relatively constant cerebral blood flow, which is critical for the normal functioning of physiological functions, as well as the occurrence, development and prognosis of the cerebral stroke.whether NBP can improve the dCA in large-artery atherosclerosis acute ischemic stroke has not been illustrated.

Thus, in this study, investigators plan to enroll 774 eligible patients, which will be randomized into either the NBP or placebo group in a 2:1 ratio within 90 days follow-up to explore whether NBP can improve the dCA in large-artery atherosclerosis acute ischemic stroke. DCA measurement will be performed at 0, 10-14 and 83-97 days after entering the trial, nurses will collect intravenous blood 6ml 3 times (each time before dCA measurement, the blood samples will be stored for laboratory test). High resolution nuclear magnetic resonance will conduct twice (0, 83-97days after entering the trial). Clinical information, neuroimaging data, biochemical examinations and follow-up information will be collected and recorded in case report form (CRF) once signing of informed consent.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effectiveness of Butylphthalide on Dynamic Cerebral Autoregulation in Patients With Large-artery Atherosclerosis Acute Ischemic Stroke(EBCAS)
Actual Study Start Date : February 28, 2018
Estimated Primary Completion Date : November 25, 2020
Estimated Study Completion Date : February 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Atherosclerosis

Arm Intervention/treatment
Experimental: butylphthalide(NBP)
Based on the standard medical care, 25mg of NBP injection, and 100ml of 0.9% saline; NBP capsule
Drug: butylphthalide(NBP)
Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2014), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.In addition, 25mg butylphthalide(NBP) injection, and 100ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, infusion for 14 days, then, butylphthalide(NBP) capsule for 76 days.

Placebo Comparator: placebo
Based on the standard medical care, 100ml of 0.9% saline as the placebo; starch capsule as the placebo
Drug: placebo
Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2014), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.In addition, 100ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, infusion for 14 days, then, starch capsule for 76 days.




Primary Outcome Measures :
  1. Phase difference (PD) in degree [ Time Frame: within 14 days injection NBP,and 90 days of sequential therapy ]
    A dCA parameter derived from transfer function analysis.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ranging from 18 to 80, both genders;
  • Within 48 hours symptoms onset;
  • According to TOAST classification, diagnosed to be large-artery atherosclerosis ischemic stroke, without history of stroke;
  • 5≤National Institutes of Health Stroke Scale (NIHSS) ≤25;
  • Unilateral internal carotid artery (ICA) or M1 segment of middle cerebral artery (MCA) stenosis (rate of stenosis ranging from 50-99%);
  • Sufficient bilateral temporal bone windows for insonation of the middle cerebral artery;
  • Glasgow Coma Scale (GCS) ≥ 8;
  • Willing to participate and sign the informed consent.

Exclusion Criteria:

  • Patients who have received or plan to undergo intravascular interventional treatment/thrombolytic therapy;
  • Coma or agitation, and can't cooperate to complete dCA;
  • Has been given drugs which can promote cerebral collateral circulation; establishment;
  • Arrhythmia, anemia and hyperthyroidism which may influence the stability of cerebral blood flow diagnosed by two physicians by electrocardiogram and laboratory tests;
  • Other intracranial diseases, including cerebral hemorrhage (primary or secondary), intracranial neoplasm, aneurysm, arteriovenous malformation, etc;
  • Alanine transaminase (ALT) or glutamic-oxalacetic transaminase (AST) continued to rise more than 3 times the upper limit of normal , creatinine clearance rate<30ml/min;
  • Pre-stroke Modified Rankin Scale (mRS) score ≥ 2;
  • Malignant neoplasm and expected lifetime < 2 years;
  • Pregnant and lactating women;
  • Participating in other trials or has been participated in other trials in recent 3 months;
  • Dementia and mental illness.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03413202


Contacts
Layout table for location contacts
Contact: Yi Yang, MD, PhD 0086-13756661217 doctor_yangyi@163.com
Contact: Zhenni Guo, MD zhen1ni2@163.com

Locations
Layout table for location information
China, Jilin
First Hospital of Jilin University Recruiting
Changchun, Jilin, China, 130000
Contact: Yi Yang, MD, PhD       doctor_yangyi@163.com   
Sponsors and Collaborators
Yi Yang
Investigators
Layout table for investigator information
Study Chair: Yi Yang, MD, PhD Neuroscience Center, Department of Neurology, The First Hospital of Jilin University
Layout table for additonal information
Responsible Party: Yi Yang, Associated Dean of First Hospital of Jilin University, The First Hospital of Jilin University
ClinicalTrials.gov Identifier: NCT03413202    
Other Study ID Numbers: EBCAS
First Posted: January 29, 2018    Key Record Dates
Last Update Posted: July 28, 2020
Last Verified: July 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Yi Yang, The First Hospital of Jilin University:
butylphthalide(NBP)
large-artery atherosclerosis acute ischemic stroke
dynamic Cerebral Autoregulation(dCA)
Additional relevant MeSH terms:
Layout table for MeSH terms
Stroke
Cerebral Infarction
Ischemia
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Pathologic Processes
Brain Infarction
Brain Ischemia
3-n-butylphthalide
Platelet Aggregation Inhibitors
Neuroprotective Agents
Protective Agents
Physiological Effects of Drugs